Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, continues to show promising results. The Canadian Phase III Psoriasis trial (SPIRIT) which commenced on December 2, 2004, includes a total of 453 patients with stable moderate to severe plaque psoriasis. The trial is currently being conducted in 32 sites and ...
New Brunswick, New Jersey and Indianapolis (ots/PRNewswire) - Johnson & Johnson and Guidant Corporation today announced that they have been notified, as anticipated, that the European Commission has decided to open a second phase review into the proposed acquisition of Guidant by Johnson & Johnson. The companies ...
Montreal, Canada (ots/PRNewswire) - Genizon BioSciences today announced the confirmation of a previously reported disease-gene location, PSORS1, as well as the identification of more than 10 new regions strongly associated with psoriasis, each containing only a limited number of genes. The company will be discussing with potential pharmaceutical partners how ...
Seattle and Mountain View, California (ots/PRNewswire) - - MPEG-4 aacPlus Provides High Quality Cross-Platform Support for PCs and Mobile Phones Loudeye Corp. (Nasdaq: LOUD), a worldwide leader in business-to-business digital media solutions, and Coding Technologies announced today that Loudeye is deploying Coding Technologies MPEG-4 aacPlus audio format ...
New York (ots/PRNewswire) - Genesis Bioventures, Inc. (AMEX:GBI) (GBI) today reported that its Annual Report on Form 10-KSB for the year ended December 31, 2004 was not filed by the deadline of Friday, April 15, 2005. The Company expects to file the 2004 annual report on or before May 15, 2005. GBI explained that the delay in filing was caused by the termination ...
Anaheim, California (ots/PRNewswire) - PharmaMar today announces the presentation of thirteen posters highlighting advances with its clinical and preclinical compounds at the 96th Annual Meeting of the American Association for Cancer Research (AACR), taking place in Anaheim, California from 16-20 April 2005. The posters include results from research on Yondelis(R), ...
Reykjavik, Iceland (ots/PRNewswire) - Theriak Medication Management, a software system from TM Software for use in healthcare operations, went into commission yesterday at a central hospital pharmacy in Bottrop, a city in the Rühr district in Germany. The pharmacy serves hospitals in the nearby cities of Oberhausen and Gelsenkirchen, which together have about five hundred in-patient beds. Spokesmen at the pharmacy say ...
Espoo, Finland (ots/PRNewswire) - The operating profit of the Orion Group for the first quarter of 2005 seems to be clearly better than that in the comparative period last year, for which the consolidated operating profit in accordance with the IFRS came to EUR 33.4 million. The good profitability is mainly consequence of the continued good sales performance and successful cost management in the Orion Pharma business division. Also the full-year net sales and ...
Madrid, Spain (ots/PRNewswire) - PharmaMar announced today that its marine-derived anti-cancer drug, YONDELIS(R) (trabectedin), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ovarian cancer. The U.S. application sponsor, is Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today that the Company has been issued U.S. Patent No. 6,878,550 for its diagnostic breath test kit, Diatest(R). The patent entitled "13C Glucose Breath Test for the Diagnosis of Diabetic Indications and Monitoring Glycemic Control" is the fifth U.S. Patent issued for this technology. ...
Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire) - - Major U.S. Public Health Initiative Complements sanofi pasteur's Leadership in Global Pandemic Preparedness Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has been awarded a $97 million contract from the U.S. Health ...
Lyon, France (ots/PRNewswire) - - First New Vaccine Against Polio in Decades to Be Used in Egypt, Part of Innovative WHO Strategy Sanofi pasteur, the vaccines business of the sanofi-aventis group, has received a license from the Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) for a new polio vaccine, which is the first new vaccine ...
Espoo, Finland (ots/PRNewswire) - At its meeting held yesterday evening, the Board of Directors of Orion Corporation, which was elected yesterday at the Annual General Meeting of Shareholders, has re-elected Erkki Etola as Vice Chairman. Orion Corporation Jukka Viinanen Olli Huotari President and CEO General Counsel ...
Princeton, New Jersey (ots/PRNewswire) - BioWa announced today that it has successfully licensed from Kyowa Hakko Kogyo Co., Ltd. (Tokyo, Osaka, Nagoya, Fukuoka, Sapporo: 4151), its parent company, the exclusive worldwide rights, except Asia, to develop and commercialize anti IL-5 receptor antibody, a potential new asthma treatment. Under the terms of the ...
Espoo, Finland (ots/PRNewswire) - At the Annual General Meeting of Orion Corporation held today, the following decisions were made: - A dividend of EUR 0.55 per share will be paid for 2004, payment date 5 April 2005. - Seven Board members were elected in accordance with the proposal by Board of Directors. Erkki Etola, Eero Karvonen, Matti Kavetvuo, Leena Palotie, Vesa Puttonen and Heikki Vapaatalo were ...
Espoo, Finland (ots/PRNewswire) - In his presentation of the 2004 Financial Statements to the Annual General Meeting of Orion Corporation, starting at 5 pm today in Helsinki, Mr. Jukka Viinanen, CEO of the Orion Group, will inform that the profitability of the Orion Group has shown very positive development in the first months of 2005 compared to the corresponding ...
Lyon, France (ots/PRNewswire) - - Vaccine Leader Looks to Introduce First Pertussis Booster for Both Adolescents and Adults in United States Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the Vaccines and Related Biological Products Advisory Committee ...
Istanbul, Turkey (ots/PRNewswire) - The inventor of extracorporeal shockwave lithotripsy (ESWL), Dornier MedTech, introduces the Compact Delta II lithotripter during the 20th annual European Association of Urology meeting. The Compact Delta II is based upon superior technology from the most widely sold lithotripter to date, the Compact Delta. This ...
Paris (ots/PRNewswire) - - New Indication Means More Patients Could Benefit From Earlier Treatment Bristol-Myers Squibb announces the approval of Taxol(r) (paclitaxel) for the treatment of early stage node-positive breast cancer following standard anthracycline and cyclophosphamide (AC) therapy. According to the approval, adjuvant treatment with Taxol should ...
Lyon, France (ots/PRNewswire) - - Submits Supplemental License Application Sanofi pasteur, the vaccines business of the sanofi-aventis Group, is seeking US government approval to broaden the age indication for its new meningococcal vaccine Menactra(TM) (Meningococcal [Groups A, C, Y and W-135] ...
Duluth, Georgia (ots/PRNewswire) - - Vaccine provides new hope for avian flu epidemic Merial today announced the introduction of a new inactivated vaccine, GALLIMUNE(R) Flu H5N9, developed and shown to be effective specifically for use against the highly pathogenic avian influenza virus H5N1 that has caused devastating economic losses in the poultry industry in Asia, and which has been linked to the deaths of ...
Zurich (ots) - Globalization is making itself felt not only worldwide but also at the regional level. The growing diversity of modern society is radically altering conditions on consumer markets. This issue was addressed at the first New Diversity Forum, which was held at the Zurich airport from March 13-14. The event, which was jointly sponsored by Lowe Switzerland ...
Indianapolis and Tokyo (ots/PRNewswire) - In three early-phase trials,(1,2,3) an investigational platelet inhibitor, prasugrel (CS-747, LY640315), demonstrated significantly higher and more consistent inhibition of platelet aggregation (IPA) compared to both placebo and the current standard of care, clopidogrel ...
Lilongwe, Malawi (ots/PRNewswire) - The Abbott Fund, Baylor College of Medicine and the Government of Malawi have announced they will partner in the establishment of Malawi's first center dedicated to providing care and treatment for children with HIV/AIDS. Construction of the new clinic on the Kamuzu Central ...
Montreal (ots/PRNewswire) - Genizon BioSciences today announced the appointment of six key scientists within the company. Tim Keith, Ph.D., has joined the company as Vice President and Chief Scientific Officer. Dr. Keith, former Head of the Human Genetics Group at Genome Therapeutics (now Oscient Pharmaceuticals), has 18 years of experience in the biotechnology ...
Antwerp, Belgium (ots/PRNewswire) - - Results from RIO-Europe trial demonstrated that first-year improvements in cardiovascular risk factors are seen through two-year study period Luc Van Gaal, M.D. Principal Investigator RIO-Europe On behalf of the RIO Steering Committee The results of a two-year phase III study in 1,507 ...
Research Triangle Park, North Carolina (ots/PRNewswire) - - Fourth quarter 2004 net revenue of US$493.2 million, up 20% from same quarter in 2003 - Record backlog of US$2.6 billion as of Dec. 31, 2004 Quintiles Transnational Corp. today announced financial results for the year and quarter ended Dec. 31, 2004. Net revenue for 2004 was US$1.78 billion versus US$1.63 billion in 2003. Contribution ...
Basel, Switzerland (ots/PRNewswire) - - New Study Published Today Provides Further Evidence of the Benefit of Avastin(R) for Patients With Advanced Colorectal Cancer Data published for the first time today in the leading Journal of Clinical Oncology showed that the unique new cancer drug Avastin keeps ...
INGELHEIM, Germany,, February 28 (ots/PRNewswire) - - Tipranavir/r More Effective Than Lopinavir/r in Large-Scale Studies of Treatment-Experienced HIV-Positive Patients New data from multiple analyses presented last week at the 12th Conference on Retroviruses and Opportunistic Infections support the efficacy of the investigational non-peptidic protease ...
Madrid, Spain (ots/PRNewswire) - PharmaMar: - Yondelis: - Due to the good results presented at the ASCO (American Society of Clinical Oncology) meeting, the randomised pivotal trial on soft-tissue sarcoma was expanded so as to compile a dossier for a regulatory application. - Results presented on ovarian cancer formed the basis for preparing Phase III trials in combination with Doxil. - The FDA (Food and Drug Administration) granted orphan ...